Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dementia01:30

Dementia

482
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
482
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Postmortem brain MRI reveals differential associations of subcortical and limbic volumes with cortical thinning and neurodegenerative pathologies.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Vulnerability of anterior medial temporal lobe subregions to early tau-related neurodegeneration in Alzheimer's disease: Converging evidence from tau-PET and plasma p-tau217.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Effects of Task-Irrelevant Talker Identity and Continuity on Spatial Selective Attention Under Interruption.

Trends in hearing·2026
Same author

Uncovering distinct spatiotemporal trajectories of T-N mismatch subtypes with likely co-pathology in Alzheimer's disease using event-based modeling.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Medial temporal lobe Tau-Neurodegeneration mismatch from structural imaging and plasma biomarkers.

Brain : a journal of neurology·2026
Same author

Temporal Modeling of Amyloid and Tau Trajectories in Alzheimer's Disease Using PET and Plasma Biomarkers.

Annals of neurology·2026

相关实验视频

Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K

技术与痴呆症 会议前会议

Dawn Mechanic-Hamilton1, Valerie Humphreys2, Danielle Hing2

  • 1Penn Alzheimer's Disease Research Center, University of Pennsylvania, Philadelphia, PA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 23, 2025
PubMed
概括
此摘要是机器生成的。

这项试点研究证明了移动认知应用性能平台 (mCAPP) 的可用性,用于在接受抗粉样蛋白疗法 (AATs) 的轻度认知障碍 (MCI) 或阿尔茨海默病 (AD) 患者中进行远程认知评估. 该应用程序显示了在治疗期间跟踪认知变化的前景.

更多相关视频

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

相关实验视频

Last Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K
The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

科学领域:

  • 神经学 神经学
  • 数字健康数字健康
  • 认知科学 认知科学

背景情况:

  • 参与移动认知评估对于监测治疗有效性和安全性至关重要,特别是在新的抗粉样蛋白疗法 (AAT) 中.
  • 现有的方法可能无法完全捕捉AAT期间的认知变化或患者参与.
  • 远程监控对于患者的方便和数据收集越来越重要.

研究的目的:

  • 评估在家进行认知评估的移动认知应用性能平台 (mCAPP) 的可行性和可用性.
  • 在接受AAT的轻度认知障碍 (MCI) 或轻度阿尔茨海默病 (AD) 患者中收集远程认知性能数据.
  • 评估mCAPP措施的初始可靠性和有效性.

主要方法:

  • 一项试点研究涉及11名参与者 (MCI或轻度AD,粉样蛋白阳性) 接受AAT.
  • 参与者在临床和家中使用了游戏化的mCAPP应用程序,长达三个月.
  • 收集的数据包括mCAPP的表现,技术使用问卷和传统的神经心理测试.

主要成果:

  • 参与者与mCAPP (1-3次/周在家中) 一贯进行,具有良好的可用性评分 (7.1/9).
  • 任务难度被大多数参与者认为是合适的.
  • mCAPP任务表现出对认知负载的敏感性,并与一些标准认知指标显示相关性.

结论:

  • mCAPP是一种可用的工具,用于在接受AAT的患者的临床和家庭认知评估.
  • 初步发现表明mCAPP在跟踪认知表现方面具有可靠性和有效性.
  • 未来的研究将专注于纵向分析和实践效应.